Royal Bank of Canada has reiterated its confidence in Zoom Communications by reaffirming an “outperform” rating and setting a $100.00 price objective. This positive assessment highlights Zoom’s continued potential in the eyes of analysts, with other research reports also signaling optimism for the tech company.

Regeneron Pharmaceuticals has struggled to keep pace with the broader pharma market over the past year. Despite this underperformance, analysts see potential for growth, citing reasons for continued optimism.